<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3411">
  <stage>Registered</stage>
  <submitdate>19/12/2011</submitdate>
  <approvaldate>19/12/2011</approvaldate>
  <nctid>NCT01498887</nctid>
  <trial_identification>
    <studytitle>Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy</studytitle>
    <scientifictitle>A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.</scientifictitle>
    <utrn />
    <trialacronym>EARLiMS</trialacronym>
    <secondaryid>2011-003484-30</secondaryid>
    <secondaryid>CFTY720DES03</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsing Remitting Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fingolimod (FTY720)

Experimental: Fingolimod - Both groups of patients in the study will be treated in parallel with Fingolimod.


Treatment: drugs: Fingolimod (FTY720)
Fingolimod will be used in two group of patients with treatment different characteristics at baseline

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Difference on Annual Relapse Rate for both groups - The annual relapse rate will be calculate for both groups based on the number of patients examined, total number of relapses for all patients and the total of days that the subject take the medication</outcome>
      <timepoint>12 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first relapse - A Kaplan-Meier method will be used to calculate time to first relapse in both groups, indicating the percentage of release-free patients at month 12 for naive and pre-treated patients</outcome>
      <timepoint>12 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disability progression - Differences between Expanded Disability Status Scale score in naive patients versus and pre-treated ones compare to baseline</outcome>
      <timepoint>12 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients diagnosed with multiple sclerosis, according to the 2010 revised McDonald
             criteria, with a relapsing-remitting course, and with at least 9 T2 lesions consistent
             with the disease, with disease duration greater than or equal to one year and less
             than or equal to five years.

          -  Patients who have had at least two relapses in the past two years and an Expanded
             Disability Status Scale score between 0 and 3.5, inclusive.

        Patients

          -  Treatment naïve: patients who have never been treated with a Disease Modifying Therapy
             or

          -  Previously treated with a first-line Disease Modifying Therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who have received treatment with:

        Fingolimod at any time (e.g. participation in a fingolimod clinical trial),
        Immunosuppressant drugs such as azathioprine or methotrexate at any time; Immunoglobulins
        in the past 6 months. Monoclonal antibodies including natalizumab, Cladribine,
        cyclophosphamide or mitoxantrone, at any time.

        - Other protocol defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>21/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>349</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>23/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Novartis Investigative Site - East Gosford</hospital>
    <hospital>Novartis Investigative Site - Kanwal</hospital>
    <hospital>Novartis Investigative Site - Liverpool</hospital>
    <hospital>Novartis Investigative Site - New Lambton Heights</hospital>
    <hospital>Novartis Investigative Site - Sydney</hospital>
    <hospital>Novartis Investigative Site - Auchenflower</hospital>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <hospital>Novartis Investigative Site - Box Hill</hospital>
    <hospital>Novartis Investigative Site - Fitzroy</hospital>
    <hospital>Novartis Investigative Site - Melbourne</hospital>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <hospital>Novartis Investigative Site - Nedlands</hospital>
    <hospital>Novartis Investigative Site - Bedford Park</hospital>
    <hospital>Novartis Investigative Site - Brisbane Queensland</hospital>
    <hospital>Novartis Investigative Site - Geelong VIC</hospital>
    <postcode>2250 - East Gosford</postcode>
    <postcode>2259 - Kanwal</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode> - Adelaide</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3011 - Fitzroy</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>SA 5042 - Bedford Park</postcode>
    <postcode>4029 - Brisbane Queensland</postcode>
    <postcode>3220 - Geelong VIC</postcode>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Asturias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla la Mancha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla y Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla y León</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Las Palmas de G.C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pais Vasco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Las Palmas de Gran Canaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santa Cruz de Tenerife</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the efficacy of fingolimod in patients with short duration
      relapsing-remitting multiple sclerosis who have not been previously treated with
      disease-modifying therapies (DMTs), versus patients with the same disease duration who have
      previously received first-line Disease Modifying Therapies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01498887</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>